Business · 15/09/2026Updated: 10/17/2026 · 1 min read
National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers
Summary
The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.